REVLIMID may cause serious side effects.
See "What is the most important information I should know about REVLIMID?"
Serious skin reactions. Serious skin reactions can happen with REVLIMID and may cause death. Call your healthcare provider right away if you have any skin reaction while taking REVLIMID.
Tumor lysis syndrome. Metabolic complications that can occur during treatment of cancer and sometimes even without treatment. These complications are caused by the breakdown products of dying cancer cells and may include the following: changes to blood chemistry, high potassium, phosphorus, uric acid, and low calcium consequently leading to changes in kidney function, heart beat, seizures, and sometimes death.
Common side effects of REVLIMID are:

diarrhea
itching
rash
tiredness
These are not all the possible side effects of REVLIMID. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store REVLIMID?

Store REVLIMID at room temperature, 59°F to 86°F (15°C to 30°C).
Keep REVLIMID and all medicines out of the reach of children.

General information about REVLIMID

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take REVLIMID for conditions for which it was not prescribed. Do not give REVLIMID to other people, even if they have the same symptoms you have. It may harm them and may cause birth defects.

This Medication Guide provides a summary of the most important information about REVLIMID. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about REVLIMID that is written for healthcare professionals. You can also call 1-888-423-5436 or visit www.REVLIMID.com.

What are the ingredients in REVLIMID?

Active ingredient: lenalidomide

Inactive ingredients: lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate.

The 5 mg and 25 mg capsule shells contain gelatin, titanium dioxide and black ink. The 10 mg capsule shell contains gelatin, FD&C blue #2, yellow iron oxide, titanium dioxide and black ink. The 15 mg capsule shell contains gelatin, FD&C blue #2, titanium dioxide and black ink.

Manufactured for Celgene Corporation

Summit, NJ 07901

This Medication Guide has been approved by the US Food and Drug Administration.

REVLIMID®, RevAssist®, and THALOMID® are registered trademarks of Celgene Corporation.

U.S. Pat. Nos. 5,635,517; 6,045,501; 6,281,230; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 6,908,432; 7,119,106; 7,189,740; 7,465,800

©2005-2010 Celgene Corporation, All Rights Reserved.

RevPlyMG.010 10/10
Revlimid (lenalidomide) Capsules, 5 mg - 28 Count Bottle
Revlimid (lenalidomide) Capsules, 10 mg - 28 Count Bottle
Revlimid (lenalidomide) Capsules, 15 mg - 21 Count Bottle
Revlimid (lenalidomide) Capsules, 25 mg - 21 Count Bottle
REVLIMID
lenalidomide capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG NDC Produc